News Article | May 23, 2017
Louis Gagnon recently joined the MyBrainSolutions (MBS) team as CEO. Gagnon has 25 years of experience as a high-growth global digital businesses leader, most notably at Amazon’s subsidiary Audible where he served as Chief Product and Marketing Officer. He also was recently appointed Advisor to TPG Capital following a short CEO assignment to turn around portfolio company Ride.com. Other past notable roles include Chief Product & Marketing Officer at Yodle and Senior VP of Global Products at Monster Worldwide. As the new CEO of MBS and Brain Resource Limited, Gagnon intends to leverage the company’s valuable assets to accelerate momentum of 60% YoY revenue growth. More specifically, the company’s Holistic Brain Assessment/Training tools and its standardized Neuroscientific Database will be used to empower individuals to assess and optimize the core brain processes that power their wellbeing. “I have spent my career focused on creating social change while generating successful shareholder outcomes,” said Gagnon. “Brain Resource is the largest shareholder value creation opportunity that I have been associated with and it also is the largest social change opportunity. I am very humbled and grateful for the work that has led us here and I cannot be more excited to build the team and execute the strategy that will take this great work to the next level.” Added MBS Chairman and co-founder Dr. Evian Gordon, “Louis is an extremely well-credentialed leader of high-growth technology-based companies who has a significant personal interest in brain performance. He has extensive relationships across the technology and investment community and provides shareholders with a proven track record of establishing market adoption and repeat purchase of innovative products in high frequency.” Another new addition, Emil Vasilev, comes to MBS with well-rounded experiences across the technology, private equity and investment banking arenas. Having worked as an investment banker at Barclays Capital and investor at Corsair Capital, Vasilev brings in-depth knowledge of finance, capital raising, transaction execution and strategy. He also has hands-on experience overseeing the finance and operations functions at Ride, a portfolio company of TPG Growth. Vasilev has expressed enthusiasm to align with MBS at a time when the importance of a holistic approach to the brain, corporate and personal well-being is becoming the norm among corporates and business leaders around the world. “I am excited to join MBS and help execute the new plan for the company while leveraging its existing marquee assets,” concluded Vasilev. “Their scientific foundation and blue-chip client base are testament to the significant opportunity for shareholder and social value-creation.” Vasilev is an eager practitioner of mindfulness meditation and holistic brain practices and volunteers as a teacher of stress management techniques and meditation. He holds a Bachelor’s degree in Economics from Amherst College. About MyBrainSolutions [parent company Brain Resource Ltd (ASX: BRC)] MyBrainSolutions is an online integrated self-empowerment platform to assess the brain and provide engaging digital health tools to train new habits and improve brain health. The platform is the first to bring together a brain-based assessment with tools to reduce stress and improve cognitive and emotional functions for employees and customers using scalable, confidential and cost-effective methods. MyBrainSolutions is owned by a subsidiary of Brain Resource Limited, which is also commercializing iSPOT products powered by the largest standardized and integrated database on the brain. For more information, please visit http://www.mybrainsolutions.com. About the NALA™ The NALA offers small and medium-sized businesses effective ways to reach customers through new media. As a single-agency source, the NALA helps businesses flourish in their local community. The NALA's mission is to promote a business' relevant and newsworthy events and achievements, both online and through traditional media. For media inquiries, please call 805.650.6121, ext. 361.
News Article | May 25, 2017
Mr. Gatto commented, "I am humbled by the opportunity to continue to build upon Fred's legacy and fulfill his vision for Callon Petroleum. I am honored to have been chosen by the Board to continue my strong partnership with Callon's Chief Operating Officer, Gary Newberry as together we lead our experienced management team in the execution of our growth initiatives that we believe will create differentiated value for our shareholders. We are all committed to ensuring a smooth transition and to honoring Fred's memory through a continued commitment to our core values. We will always be profoundly grateful for his friendship and leadership, and he will be deeply missed by our organization as well as the oil and gas industry. During this time, all of our thoughts are with Fred's family and we will do everything we can to support them." Prior to joining Callon, Mr. Gatto held various positions in the financial advisory and energy investment banking groups of Merrill Lynch & Co., Barclays Capital, Merrill Lynch Commodities, Inc. and MarchWire Capital, LLC, which he founded. Mr. Gatto graduated from Cornell University with a BS degree and The Wharton School of the University of Pennsylvania with an MBA. Mr. Flury has served on the Board since 2004 and currently serves on the Company's Audit, Compensation and Strategic Planning and Reserves Committees. Prior to his retirement, Mr. Flury spent over 30 years with Amoco Corporation, and later, BP p.l.c., most recently as Chief Executive, Gas and Power and Renewables. Mr. Flury is also a director and the non-executive Chairman of Chicago Bridge and Iron Company, N.V. Callon is an independent energy company focused on the acquisition, development, exploration, and operation of oil and gas properties in the Permian Basin in West Texas. This news release is posted on the Company's website at www.callon.com and will be archived there for subsequent review under the "News" link on the top of the homepage. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/callon-petroleum-company-announces-appointment-of-joseph-gatto-jr-as-chief-executive-officer-and-l-richard-flury-as-chairman-following-unexpected-death-of-fred-callon-300464292.html
News Article | May 26, 2017
TULSA, Okla., May 26, 2017 /PRNewswire/ -- Magellan Midstream Partners, L.P. (NYSE: MMP) announced today that Aaron Milford, chief financial officer, is scheduled to participate in a question and answer session about Magellan at the 2017 Investor Conference hosted by the Master Limited Partnership Association at 1:40 p.m. Eastern on Thurs., June 1 in Orlando, Florida. The session will be moderated by Rick Gross of Barclays Capital, with an audio webcast available live on the day of the event on the partnership's website at www.magellanlp.com/investors/webcasts.aspx. A replay of the webcast also will be available for 30 days at www.magellanlp.com.
News Article | May 10, 2017
NEW YORK--(BUSINESS WIRE)--First Eagle Investment Management is pleased to announce that First Eagle Global Income Builder Fund (the Fund) marked its five-year anniversary on May 1, 2017. The Fund had an average annualized return of 6.82% for the institutional class shares (FEBIX), outperforming its Morningstar World Allocation category median by 1.29% over the five-year period ended May 1, 2017. The overall multi-asset income strategy had total net assets of $3.1 billion globally, of which the Fund represented $1.3 billion. Aiming for both current income and long-term growth of capital, the Fund employs a highly flexible, benchmark-agnostic approach. Based on in-house bottom-up research, co-managers Kimball Brooker, Edward Meigs and Sean Slein select equities and fixed income investments from around the globe. Downside protection—defined as the avoidance of permanent impairment of capital—is a key area of focus. The Fund is available in share classes directed at individual investors, institutions and participants in group retirement plans. “When we launched the fund in 2012, we thought that historically low interest rates were likely to challenge income investors for years to come. We looked to our fixed income allocation for the potential ballast of sustainable income and to our equity allocation for dividend income and potential real growth relative to inflation,” said Kimball Brooker, deputy head of the Global Value team and portfolio manager. “By staying true to what we believe is a prudent investment philosophy—taking on less credit risk and not chasing yield—we have tended to differ from our peers. We go where we believe the opportunities are, but we are very cognizant of risk.” The Morningstar percentile rankings for the First Eagle Global Income Builder Fund in the Morningstar World Allocation category were derived using the total return of the performance figure associated with its 1-, 3- and 5-year time periods as of 05/01/17. First Eagle Global Income Builder Class I: Morningstar percentile rankings were: 38% for the 1-year (179/467), 33% for the 3-year (130/402) and 19% for the 5-year (62/335) when compared against the Morningstar World Allocation category. Different share classes have different ratings. “In a low-yield environment where rates have been expected to normalize, financial advisors have been eager to find investment solutions for their clients that can provide sustainable income without undue exposure to interest-rate risk,” said Robert Bruno, head of retail distribution at First Eagle Investment Management and president of FEF Distributors. “Many advisors have turned to our fund over the last five years, giving their clients the potential to benefit from its solid investment performance.” First Eagle is an independent investment management firm that manages approximately $105 billion in assets (as of 3/31/17) on behalf of institutional and individual clients. With the core purpose of providing prudent stewardship of client assets, the firm offers active, fundamental, benchmark-agnostic strategies, with a strong focus on downside protection. First Eagle’s investment capabilities include equity, fixed income and multi-asset strategies. Over a long history dating back to 1864, First Eagle has helped its clients avoid permanent impairment of capital and earn attractive returns through widely varied economic cycles—a tradition that is central to its mission today. First Eagle Investment Management is the adviser to First Eagle Funds. For more information, please visit www.feim.com. Private equity funds owned by The Blackstone Capital Partners and Corsair Capital own a majority stake in First Eagle Investment Management. The performance data quoted herein represents past performance and does not guarantee future results. Market volatility can dramatically impact the Fund’s short-term performance. Current performance may be lower or higher than figures shown. The investment return and principal value will fluctuate so that an investor’s shares, when redeemed, may be worth more or less than their original cost. Past performance data through the most recent month end is available at www.feim.com or by calling 800.334.2143. * The annual expense ratio is based on expenses incurred by the Fund, as stated in the most recent prospectus. Had fees not been waived and/or expenses reimbursed in the past, returns would have been lower. Class I Shares require $1mm minimum investment, and are offered without sales charge. Performance information is for class I Shares without the effect of sales charges and assumes all distributions have been reinvested and if a sales charge was included values would be lower. Class A and C Shares have maximum sales charges of 5.00% and 1.00% respectively, and 12b-1 fees, which reduce performance. °° The composite index consists of 60% of the MSCI World Index and 40% of the Bloomberg Barclays U.S. Aggregate Bond Index. There are risks associated with investing in securities of foreign countries, such as erratic market conditions, economic and political instability and fluctuations in currency exchange rates. These risks may be more pronounced with respect to investments in emerging markets. Investments in bonds are subject to interest-rate risk and can lose principal value when interest rates rise. Bonds are also subject to credit risk, in which the bond issuer may fail to pay interest and principal in a timely manner, or that negative perception of the issuer’s ability to make such payments may cause the price of that bond to decline. High yield securities (commonly known as “junk bonds”) are generally considered speculative because they may be subject to greater levels of interest rate, credit (including issuer default) and liquidity risk than investment grade securities and may be subject to greater volatility. The Fund invests in high yield securities that are non-investment grade. High yield, lower rated securities involve greater price volatility and present greater risks than high rated fixed income securities. High yield securities are rated lower than investment grade securities because there is a greater possibility that the issuer may be unable to make interest and principal payments on those securities. Bank loans are often less liquid than other types of debt instruments. There is no assurance that the liquidation of any collateral from a secured bank loan would satisfy the borrower’s obligation, or that such collateral could be liquidated. Income generation is not guaranteed. If dividend paying stocks in the Fund’s portfolio stop paying or reduce dividends, the Fund’s ability to generate income will be adversely affected. The principal risk of investing in value stocks is that the price of the security may not approach its anticipated value or may decline in value. Investment in gold and gold related investments present certain risks, and returns on gold related investments have traditionally been more volatile than investments in broader equity or debt markets. Physical gold does not produce income. All investments involve the risk of loss or principal. 2017 Morningstar, Inc.© All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results. The MSCI World Index is a widely followed, unmanaged group of stocks from 23 developed market countries and is not available for purchase. The index provides total returns in U.S. dollars with net dividends reinvested. One cannot invest directly in an index. The Bloomberg Barclays Capital U.S. Aggregate Bond Index is a broad-based unmanaged benchmark that measures the investment grade, U.S. dollar-denominated, fixed-rate taxable bond market, including Treasuries, government-related and corporate securities, MBS (agency fixed-rate and hybrid ARM passthroughs), ABS, and CMBS, and is not available for purchase. Investors should consider investment objectives, risks, charges and expenses carefully before investing. The prospectus and summary prospectus contain this and other information about the Funds and may be obtained by asking your financial adviser or calling us at 800.334.2143. Please read our prospectus carefully before investing. For further information about the First Eagle Funds, please call 800.334.2143.
News Article | February 16, 2017
WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that the Company will present at the Barclays Capital Global Healthcare Conference on Wednesday, March 15, 2017 at 3:20 p.m. ET at the Loews Hotel in Miami. Robert Friel, PerkinElmer’s chairman and chief executive officer, will provide an overview of the Company and its strategic objectives. A live audio webcast of the presentation will also be available on the Investors section of the Company's website at www.perkinelmer.com. A replay of the presentation will be posted on the PerkinElmer website after the event and will be available for two weeks following. PerkinElmer, Inc. is a global leader focused on innovating for a healthier world. The Company reported revenue of approximately $2.1 billion in 2016, has about 9,000 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com.
News Article | March 1, 2017
BRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ (Characterized Oral Desensitization ImmunoTherapy) treatments for life-threatening food allergies, today announced that CEO Stephen Dilly, M.B.B.S., Ph.D., will present a company overview at the Cowen and Company 37th Annual Health Care Conference on Wednesday, March 8, 2017, at 10:00 a.m. Eastern Time and at the Barclays Capital Global Healthcare Conference on Thursday, March 16, 2017, at 11:15 a.m. Eastern Time. The live webcasts of the presentations will be accessible on the Events page under the Investor Relations section of the Aimmune website at www.aimmune.com. The replays of the webcasts will be available for at least 30 days following each webcast. Aimmune Therapeutics, Inc., is a clinical-stage biopharmaceutical company developing treatments for life-threatening food allergies. The company’s Characterized Oral Desensitization ImmunoTherapy (CODIT™) approach is intended to achieve meaningful levels of protection by desensitizing patients with defined, precise amounts of key allergens. Aimmune’s first investigational biologic product using CODIT™, AR101 for the treatment of peanut allergy, has received the FDA’s Breakthrough Therapy Designation for the desensitization of peanut-allergic patients 4-17 years of age and is currently being evaluated in Phase 3 clinical trials. For more information, please see www.aimmune.com.
News Article | February 14, 2017
CLEVELAND, Feb. 14, 2017 (GLOBE NEWSWIRE) -- Parker Hannifin Corporation (NYSE: PH), the global leader in motion and control technologies, today announced that it is scheduled to present at the Barclays Capital Industrial Select Conference in Miami Beach, Florida, February 23, 2017 at 9:45 a.m. Eastern time. Parker's scheduled presenter is Tom Williams, Chairman and Chief Executive Officer. A live webcast of the presentation will be accessible on Parker's investor information website at www.phstock.com and will be archived on the site. Parker Hannifin is a Fortune 250 global leader in motion and control technologies. For 100 years the company has engineered the success of its customers in a wide range of diversified industrial and aerospace markets. Parker has increased its annual dividend per share paid to shareholders for 60 consecutive fiscal years, among the top five longest-running dividend-increase records in the S&P 500 index. Learn more at www.parker.com or @parkerhannifin.
News Article | July 17, 2008
Indian restaurant chain Tiffinbites has snapped up the Bombay Bicycle Club from Clapham House for £4.4m. The Bombay Bicycle Club runs three eat-in restaurants and 15 takeaways across London. Clapham said it would use the sale proceeds to pay down its bank debts and plough money into the development of its other restaurant brands - Gourmet Burger Kitchen, Tootsies and The Real Greek. Clapham scaled back expansion plans last December when it issued a shock profits warning after being hit by spiralling food costs and rent increases. Shares in the Aim-listed company jumped by 10.5p to 90p on news of the sale, a rise of 13%. Tiffinbites currently runs four restaurants serving healthy, low-fat Indian food to City workers at St Paul's, Canary Wharf, Moorgate and Liverpool Street. When it first entered the Square Mile five years ago it became known for its takeaways in traditional tiffin boxes - several stacked boxes with a carry handle, each box containing individual portions of curry dishes. Tiffinbites was founded by Jamal Hirani and Jonathan Marks who met at Marks & Spencer where they were buyers, and saw an opportunity in selling healthy Indian food to City workers. "I was working in the City and missing my mum's cooking," Hirani has said. Tiffinbites now delivers 2,000 lunches daily to big company offices such as O2 in Slough and Barclays Capital in Canary Wharf. David Page, the Clapham founder and chairman, said at the end of last month that the company's chains had frequently attracted interest over the years and that it had waited for the "right time" to sell. Clapham itself has also been the subject of bid speculation. Its chief executive Paul Campbell said: "While we are sad to see the Bombay Bicycle Club leave our portfolio, it is predominantly a home delivery business with a different pricing point and a longer period for return on capital than our other brands." He said it was important to bolster the company's balance sheet at the current time of economic slowdown and focus on its other, pure restaurant businesses. Bombay Bicycle Club made a loss before tax of £484,000 in the year to end March, and its assets were worth £2.4m. Clapham is taking a one-off £1.9m hit from writing off goodwill on Bombay Bicycle Club.
News Article | February 20, 2017
The UK’s POD Point, a provider of electric car charging stations, is raising £9 million in fresh funding to fund its expansion across Europe. The funding is a mix of VC investment and equity crowdfunding. Draper Esprit and Barclays Capital have invested £5 million and £2 million respectively with £550,000 coming from angel investors. A remaining £1.5 million is being raised through equity crowdfunding site Crowdcube. With this investment, POD Point plans to expand into mainland Europe and will create 50 new jobs in the UK. The company said it is aiming to have a station “installed everywhere people park for an hour or more” by 2020 through its various partnerships. It recently secured partnerships with Barratt Himes, Holiday Extra, and Hyundai. The electric vehicle market in the UK is gathering momentum, said POD Point CEO Erik Fairbairn. “The way people use cars is changing and how they are powered is at the epicentre of that,” he said. “Travel shouldn’t damage the earth, which is why we are building the most advanced intelligent charging network in the UK, the POD Point Open Charge Network.” “POD point is leading the charge in the EV infrastructure market in the UK and Europe,” added Draper Esprit CEO Simon Cook. “We not only think that the EV market will develop at pace over the next decade, but that POD point is set to play a significant role in enabling adoption.
News Article | February 22, 2017
NEWARK, Calif.--(BUSINESS WIRE)--Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that the company will participate in two upcoming investor conferences. Revance management is scheduled to present at the Cowen and Company 37th Annual Health Care Conference in Boston, MA on Tuesday, March 7 at 10:00am ET. Revance management is also scheduled for a fireside chat at the Barclays Capital Global Healthcare Conference 2017 in Miami, FL on Tuesday, March 14 at 3:20pm ET. Interested parties can access the live audio webcast for both of these conferences from the Investor Relations section of the company's website at www.revance.com. The webcast replay will be available after the conclusion of the live presentation for approximately 30 days. Revance, a Silicon Valley-based biotechnology company, is committed to the advancement of remarkable science. The company is developing a portfolio of products for aesthetic medicine and underserved therapeutic specialties, including dermatology, orthopedics and neurology. Revance’s science is based upon a proprietary peptide technology, which when combined with active drug molecules, may help address current unmet needs. Revance’s initial focus is on developing DaxibotulinumtoxinA, the company’s highly purified botulinum toxin, for a broad spectrum of aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The company’s lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is currently in development for the treatment of glabellar lines, cervical dystonia and plantar fasciitis with the potential to be the first long-acting neurotoxin. The company holds worldwide rights for all indications of RT002 injectable and RT001 topical and the pharmaceutical uses of its proprietary peptide technology platform. More information on Revance may be found at www.revance.com. “Revance Therapeutics” and the Revance logo are registered trademarks of Revance Therapeutics, Inc.